Evotec
Sébastien Briois has a diverse range of work experience. Sébastien is currently working as a Software Engineering Team Lead at Evotec. Prior to this, they worked at Syngenta as a Quantitative Breeding Lead Cereals EAME and also as a Computational Biologist and Bioinformatician. In this role, they were responsible for designing and implementing a web application for exploring functional genomics data. Sébastien used MongoDB for data integration and worked with various internal and public genomes. Before Syngenta, Sébastien worked at CNRS as a Bioinformatics Engineer, where they studied DNA repair mechanisms and developed custom tools for analyzing ChIP-Chip and ChIP-Seq data. Sébastien also created a lab management web application using Python/Django. Prior to CNRS, they worked at the Wellcome Trust Sanger Institute as a Senior Software Developer, focusing on bioinformatics projects related to mouse genetics. Finally, Sébastien started their career at Sibio as a Web Developer.
Sébastien Briois completed their education with a Master of Science degree in bioinformatics and biostatistics from the University Paris between 2005 and 2007. Prior to that, they obtained an Associate's degree in computer science from the same university from 2002 to 2004. Additionally, they have obtained certifications in UX Design and Angular JS from institutions like LinkedIn and Code School.
This person is not in the org chart
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.